A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
about
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitisTreatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitisNuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interactionInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsShining a light on intestinal trafficMeta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionTargeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.Antisense approach to inflammatory bowel disease: prospects and challenges.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.The fundamental basis of inflammatory bowel disease.Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Colonic treatments and targets: issues and opportunities.Anti-adhesion molecule therapy for inflammatory bowel diseaseUlcerative colitis: immune function, tissue fibrosis and current therapeutic considerations.Future therapeutic approaches for inflammatory bowel diseases.Targeting T-cell migration in inflammatory bowel disease.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.Immunosuppressive and biologic therapy for ulcerative colitis.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis.Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature.Therapeutic innovations in inflammatory bowel diseases.Alicaforsen for the treatment of inflammatory bowel disease.Genetic risk variants as therapeutic targets for Crohn's disease.Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.Emerging drugs to treat Crohn's disease.Natalizumab: a promising treatment for Crohn's disease.Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.Alicaforsen in the treatment of pouchitis.
P2860
Q24187707-B8A0CD9B-9059-4E06-BC58-B6944F87DF34Q24234806-F30A1FBC-3C97-442A-89D9-A54877CFAD03Q24647748-421193FD-3A80-462E-B50F-31228AFB6AC1Q26785537-FBAE934C-8603-4B9E-9E51-458A61CE26D7Q26863227-A37773D9-86E4-48C5-98E0-C4AB8439AB81Q30644152-B18D218E-E73B-4B48-BA6F-5A0C964979D5Q34175958-7038825C-4241-493A-9087-BFB3850C5CC5Q34243433-80EE3339-75C7-4949-BBEF-6CDB0DFB1E0CQ34473572-095C53B4-35BA-4A41-BB59-06EAB05425A3Q35637379-819A5E26-2E09-4E48-B06B-D3BFEB4632B7Q35649436-34DA4C63-97A4-4778-A102-EF87C241948FQ35889006-4449C983-0F66-4353-9320-9F2E23F5FC02Q36616115-17FE3BE4-E276-462D-9D78-044B5B2E834EQ37188711-C244666F-A2C5-46D1-BBBC-96E535CA661EQ37321859-FC030B8D-D83B-436F-B4D4-667F3885A36FQ37530912-17A10817-AA81-4217-9146-75077C738DA9Q37823325-FB1C0377-9821-4653-AEF8-B898262318C6Q37863515-9607EAFA-E7BF-4BBE-9083-17DE7F16C108Q37870435-D237F799-CEE4-4CD1-83CE-FC763D33B9D5Q38040430-440E8258-4BB1-4B99-B773-1FF182FA8F93Q38053495-BCF1968E-422B-489C-8C4F-90B1E1AE17F7Q38060831-E1C2AD6C-46DB-4E62-8F2C-48692FC47848Q38132555-05C03462-0023-4DA5-8A5F-9CA37DE7453AQ38181018-90185772-7AEE-44FC-8201-26A9BB4D2A39Q38248635-47C21139-C6DE-4796-A09B-A07B557EBB0BQ38351464-7CABC536-6D71-464F-971C-05F281D65157Q38505808-E0DAA4BB-BA4F-4025-AEC4-422EC5C3847CQ38588839-FDA97D44-740A-4494-A2E1-E9BFB69B12E7Q38618178-8D487FF6-9A43-49B5-8AC2-AC1272E58F39Q38697244-E334AAA2-C472-4E8C-97F8-3CEEBE9C8DC8Q38915139-7FE69C2C-D22D-4FFF-AB5B-284C5B1EDABCQ38992068-393B6611-602D-45DB-AB8F-E3C186198F76Q39881787-0E3C6793-90F4-4EEA-BAB7-E2BF8760DC18Q43061578-B87E4142-FC72-4674-890C-AC5D3EC9ADC2Q47365129-D33271B5-BB8D-4170-94FB-6D3F36C39E22Q48567953-CE484DB3-6217-4881-8CCE-5417EC859E4A
P2860
A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@ast
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@en
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@nl
type
label
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@ast
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@en
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@nl
prefLabel
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@ast
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@en
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@nl
P2093
P2860
P1476
A phase II dose ranging, doubl ...... left-sided ulcerative colitis.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2006.02910.X
P407
P577
2006-05-01T00:00:00Z